At Eavono, we’re reimagining antibody drug discovery through cutting-edge science and technology. Our mission is to accelerate the development of effective, next-generation antibody therapeutics that tackle some of the toughest challenges in healthcare today.
We specialize in designing antibody candidates that precisely target specific proteins involved in disease. Using advanced computational tools, we identify binding sites, generate diverse antibody options, and optimize their characteristics to meet stringent therapeutic standards. This includes enhancing stability, reducing off-target effects, and ensuring compatibility with the human immune system.
Our proprietary technology allows us to evaluate and refine antibodies at every level, from structure and binding affinity to immunogenicity and manufacturability. By integrating these steps into an efficient, data-driven workflow, we cut down discovery timelines and maximize success rates.
Company Details
- Employees
- 2
- Founded
- -
- Address
- London , England, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://eavono.com
- Keywords
- Drug Discovery, Antibody Design, Antibody Drug Design, Molecular Modeling, Drug Development.
- HQ
- London , England
Eavono Questions
Eavono's website is http://eavono.com
Eavono's LinkedIn profile is https://uk.linkedin.com/company/eavono
Eavono has
2 employees.
View email and phone details for 2
employees at Eavono.
Eavono's industry is
Biotechnology Research
Eavono's top competitors are
Rayca Precision,
Kenya Plant Health Inspectorate Service (Kephis),
Zetta Genomics Ltd,
Dsst,
Genus Oncology Llc,
Agemica,
Icon Plc,
Gsk,
The Ladyboss Podcast,
Pfizer.
Eavono's categories are Biotechnology Research
Eavono's founding year is 2024
